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Renal failure (RF) reversal in multiple myeloma (MM) is associated with an improved prognosis. Light chain myeloma, serum
creatinine (SCr) > 4mg/dL, extensive proteinuria, early infections, and certain renal biopsy findings are associated with lower
rates of RF reversal. Our patient is a 67-year-old female with multiple poor prognostic factors for RF reversal who demonstrated
a rapid renal response with bortezomib and dexamethasone (BD) regimen. She presented initially with altered mental status.
On exam, she appeared lethargic and dehydrated and had generalized tenderness. She had been taking ibuprofen as needed
for pain for a few weeks. Labs showed a white cell count—18,900/𝜇L with no bandemia, hemoglobin 10.8 gm/dL, potassium—
6.7mEq/L, bicarbonate—15mEq/L, blood urea nitrogen—62mg/dL, SCr—5.6mg/dL (baseline: 1.10), and corrected calcium—
11.8mg/dL. A rapid flu test was positive. Imaging studies were unremarkable. Her EKG showed sinus tachycardia and her urinalysis
was unremarkable. The unexplained RF in an elderly individual in conjunction with hypercalcemia and anemia prompted a MM
work-up; eventually, lambda variant MM was diagnosed. An immediate (4 days) renal response defined as 50% reduction in SCr
was noticed after initiation of the BD regimen.
1. Introduction
Renal failure (RF) is common in multiple myeloma (MM)
[1] and is associated with a poor prognosis [2, 3]. The
pathology of RF in MM is heterogeneous [4]; it is most often
associated with immunoglobulins, especially free light chain
(FLC) deposition [5–8]. FLC can cause broad spectrum of
renal lesions [9, 10]; myeloma cast nephropathy (MCN) is
the most common [5, 11]. FLC damages kidneys due to its
direct toxic effect on proximal convoluted tubules (PCT)
and subsequently triggers inflammatory pathways and cast
formation [6]. Excess FLC production in MM beyond the
endocytosis capacity of the PCT initiates this renodestructive
cascade [12]. Of note, the extent of renal disease does not
correlate with quantity of the FLC. This variable toxicity
can be attributable to the functional and morphological
differences of the FLC subtypes—Kappa (𝜅)/Lambda (𝜆) [13–
15] apart from the status and influence of the concomitant
comorbidities in MM, for example, dehydration, hypercal-
cemia [16], and infections [7, 8, 17, 18].
Reversal of RF in MM is associated with improved sur-
vival [2]; FLC myeloma, serum creatinine (SCr) > 4mg/dL,
extensive proteinuria, early infections, and certain renal
biopsy findings (interstitial fibrosis and more tubular casts)
are associated with lower rates of RF reversal [19–21]. Inter-
estingly, female gender was also associated with poor RF
recovery in Rota et al.’s study [22], but this association was
not consistent in other studies.
With the advent of novel agents, such as thalidomide
and bortezomib with/without high-dose dexamethasone,
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RF reversal rates have improved [23–26]. Further studies on
novel agents reported bortezomib plus high-dose dexametha-
sone (BD) regimen to bemore efficacious and possibly having
renal protective effect [27–35]; therefore, this combination
has become preferred therapy inMMwith RF [36]. However,
poor prognostic factors for RF reversal persisted even with
these newer agents [24, 34].
We present a MM case with multiple poor prognostic
factors for RF reversal (i.e., 𝜆 LC MM, severe acute RF with
SCr of >4mg/dL, eGFR < 15mL/min, and female gender)
demonstrating a rapid renal response with the BD regimen.
A renal response was defined as 50% reduction in SCr;
compared to the pretreatment values [25, 37], the renal
response time in our case was short (4 days) andwas achieved
with chemotherapy alone without adjunctive plasmapheresis
or dialysis.
2. Case
A 67-year-old female presented with an acute change in
mental status manifested as confusion, transient aphasia, and
brief phase of unresponsiveness. She had generalizedmalaise,
body aches, and fatigue of few days’ duration. She had been
taking ibuprofen tablets—200mg every 4–6 hours as needed
for pain since few weeks. She was hospitalized ten days prior
for viral gastroenteritis (GE); then, she received contrast for
CT abdomen and pelvis (A & P) which ruled-out intra-
abdominal pathology.
Past medical history included well-controlled treated
hypertension (HTN), chronic kidney disease (CKD) stage III
(baseline SCr 1.10mg/dL), anemia of chronic disease (ACD),
chronic back pain secondary to lumbar disk degenerative
disease, and polymyalgia rheumatica (PMR). Home medi-
cations included Lisinopril, Multivitamins, and Prednisone
(2mg twice daily for PMR). Family history is negative for
any autoimmune disorders orMM. She is a reformed smoker,
social drinker, and denied illicit drug use ever.
Physical examination revealed a Caucasian female who
was lethargic but responsive to verbal stimuli, oriented
to person and not to place and time. Other significant
findings included dry oral mucosa, generalized abdominal,
and extremity tenderness. She was afebrile and the rest of
the vitals included blood pressure—84/53mmHg, pulse—
104 beats/minute and regular, respiratory rate—16/minute,
and pulse oximetry—96% on room air.
Laboratory investigations at the time of admission
included Complete Blood Count (CBC), Basic Metabolic
Panel (BMP), hepatic panel, urinalysis, blood cultures, and
few others. CBC showed white blood cell (WBC) count—
18,900/𝜇L with no bandemia, hemoglobin—10.8 gm/dL, and
platelets—211,000/𝜇L. BMP showed sodium (Na)—
132mEq/L, potassium—6.7mEq/L, chloride—100mEq/L,
bicarbonate—15mEq/L, blood urea nitrogen (BUN)—
62mg/dL, SCr—5.60mg/dL, glucose—96mg/dL, calcium—
11.2mg/dL, magnesium—1.8mg/dL, and phosphorous
of 4.5mg/dL. Lactate was 1.0mg/dL. Hepatic panel was
unremarkable other than mild hypoalbuminemia of
3.2mg/dL, thus making corrected calcium of 11.8mg/dL.
Urine (U) dip-stick showed small protein (1+), and blood;
U microscopy was negative for any kind of casts. U-Na—
100mEq/L, U-Cr—29mg/dL, U-specific gravity (U-SG)—
1.007, U-protein—321.0mg/dL, andU-albumin—58.4mg/dL;
therefore, U-albumin excretion (UAE) was 2.01, and
fractional excretion of Na (FENa) was 14.6%. Estimated GFR
(eGFR)was 7.0mL/min. Chest X-ray (CXR) did not show any
cardiopulmonary disease. CT brain ruled out stroke. Non-
contrast CT A & P did not show any acute intra-abdominal
pathology; there was no evidence of hydronephrosis, masses,
or lymphadenopathy. EKG showed sinus tachycardia without
any changes specific to hyperkalemia. Rapid influenza test
was positive for type B virus.
She was admitted with working diagnoses of severe sepsis
secondary to influenza, acute RF, hyperkalemia, and hyper-
calcemia. She was started on oseltamivir treatment (75mg
oral twice daily for 10 days) for severe influenza. Intravenous
fluids were initiated; bicarbonate, dextrose plus insulin, and
sodium polystyrene were given for hyperkalemia. Over the
initial couple of days, her mental status and hemodynamics
improved; leukocytosis and electrolyte abnormalities got
normalized. Her urine output has been adequate. However,
RF continued toworsen despite fluid resuscitation, correction
of hypercalcemia, and avoidance of nephrotoxins. She did
not have any clinical indications that would have warranted
dialysis. In view of this unexplained acute RF in an elderly
female with concomitant findings of hypercalcemia and
chronic anemia, we considered the possibility of MM and
ordered serumprotein electrophoresis (SPEP). SPEP revealed
monoclonal M spike in the beta region. Serum M protein
concentration was 0.5 gm/dL and all immunoglobulin levels
were low suggestive of hypogammaglobulinemia. Serum and
urine immunofixation (IFE) were positive for monoclonal
gammopathy in lambda region. Serum FLC analysis showed
𝜅 LC levels at 4.56mg/L (normal range: 3.30–19.40mg/L)
and 𝜆 LC levels 21,480mg/L (5.70–27.60mg/L) with 𝜆/𝜅
ratio of 4710. FLC levels were confirmed with dilution. Bone
marrow biopsy was performed; Wright Giemsa staining of
the bone marrow aspirate demonstrated more than 50% of
morphologically variable plasma cells characteristic of MM
(Figure 1), and immunohistochemistry confirmed lambda LC
restricted plasma cells (Figure 2). Bone survey with plain
radiographs for prognostic evaluation and risk stratification
was considered, but the patient declined. Imaging studies
done in the past were reviewedwhich included CT brain, A&
P, and CXR; chronic bilateral sacral fractures and osteopenia
with cystic changes in femoral headwere observed; therewere
no lytic lesions characteristic of MM.
Chemotherapy with bortezomib (1.3mg/m2 subcuta-
neous injection on days 1, 4, 8, and 11 q. 21 days schedule)
and high dose dexamethasone (20mg per oral daily for 5 days
a week) was initiated promptly after the diagnosis of MM.
There was a 50% reduction in SCr and SFLC concentration
after two doses of bortezomib and five days of dexamethasone
(Figure 3). She was discharged home with an outpatient
chemotherapy arrangement. Her renal function improved
with SCr to 2.5mg/dL and eGFR to 18mL/min after two
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Figure 1:Wright-Giemsa stain of the bonemarrow aspirate demon-
strating more than 50% of morphologically variable plasma cells
including binucleate forms (black arrows), mature plasma cells with
large basophilic cytoplasm, eccentric nucleus with perinuclear halo
and clock face chromatin (orange arrows), and immature cells with
high nuclear-cytoplasm ratio and dispersed chromatin (red arrows).
Figure 2: Immunohistochemistry of the bone marrow biopsy
showing positivity for lambda light chains.
chemotherapy cycles and stabilized thereafter while lambda
light chains were still elevated at 11,300mg/L.
3. Discussion
The initial differential diagnoses considered for an acute
RF in our case included (i) prerenal—due to hypovolemia
secondary to viral GE and sepsis induced hypotension; and
(ii) intrinsic renal—acute tubular necrosis (ATN) due to
prolonged hypovolemia and/or nephrotoxins (NSAIDs and
CT contrast), or allergic interstitial nephritis (AIN). CT A &
P done at the index hospital admission ruled out obstructive
uropathy. Preliminary work-up including the urine studies
did not support a prerenal etiology (i.e., BUN/SCr ratio∼11 : 1,
U-Na: 100mEq/L, FENa∼14%, and U-SG: 1.007) and the
bland urine sediment was less likely to suggest ATN or AIN.
MM was considered in this setting of an unexplained RF in
an elderly individual [8, 38]; furthermore, the concomitant
findings of hypercalcemia, ACD, and bone pains, as in
our case, improves diagnostic sensitivity for MM, which
prompted us to do relevant investigations (SPEP, IFE, and




























represents the days ( 8th and 12th) of
bortezomib administration in the hospital
Figure 3: Serum creatinine trend over the course of the hospitaliza-
tion.
Of note, her SCr was 1.01mg/dL during the previous
hospitalization with viral GE, 10 days prior to the index
hospitalization. On this admission, the LC concentration in
the renal tubules might have reached a toxic level, the effect
of which could have been further precipitated by hypoten-
sion due to viral GE/sepsis, hypercalcemia, and nephrotox-
ins (NSAID’s and CT contrast). While RF in our patient
could be multifactorial due to hypotension, hypercalcemia,
and nephrotoxins, it is important to note that there was
worsening of the renal function despite correction of the
above mentioned factors. Furthermore, the prompt renal
response noticed to chemotherapy favorsMMas the principle
underlying etiology of acute RF. We deferred renal biopsy as
the clinical presentation and laboratory investigations (𝜆 LC
MM, low UAE [39], and bland urine sediment) in our case
were highly suggestive of MCN. Moreover, it was felt that the
procedural risks of the biopsy would outweigh the limited
prognostic information it would confer.
The main strategy in the management of RF in MM
is to lower FLC concentration immediately. FLC con-
centration can be lowered by slowing their production
through chemotherapy, mechanical removal through dialy-
sis/plasmapheresis, and diluting FLC in renal tubules through
hydration and removal of factors precipitating cast formation.
Previously, mechanical removal of FLC was the most often
sorted treatment strategy [40, 41]; furthermore, lack of effec-
tive antimyeloma chemoagents hindered renal recovery, thus
leading to greater dialysis dependency and deaths in the past
[39]. With the advent of rapid acting novel agents showing
improved renal recovery, myeloma response, and over-all
prognosis, prompt chemoinitiation with bortezomib-based
regimen has become the standard strategy [42]. Sometimes,
patients might have been already initiated on hemodialysis
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for advanced RF with a pending or established diagnosis of
MM; in this dialysis-dependent population as well, borte-
zomib was shown to be well tolerated [43, 44] compared to
other conventional chemoagents [45, 46] and, furthermore,
novel agents in combination with high-dose dexamethasone
improved renal function rapidly to become independent of
dialysis sooner [23, 44].
Most commonly, renal recovery correlates with reduction
in SFLC load as noticed in our case; this association has been
particularly reported in newly diagnosedMM[37] and biopsy
proven MCN [47]—Leung et al. reported that renal response
was not noticed unless there was a 50% or more reduction
in SFLC load and suggested to consider plasmapheresis as a
bridge or adjunctive therapy in biopsy provenMCN cases not
responding immediately to chemotherapy as the chronicity
of RF can affect the degree of recovery. Otherwise, there are
no standard recommendations on when to resort to plasma-
pheresis in case of MM nonresponsive to chemotherapy. Few
studies evaluated combination strategies, that is, mechanical
approaches in adjunct to novel agents [48, 49] in lowering
SFLC load. But, they were limited in providing information
on the relative contribution of mechanical removal and,
furthermore, early reduction in SFLC load probably reflects
the efficacy of the chemotherapy [50]; rapid reduction in
SFLC load in our case with just BD regimen alone supports
the later.
In conclusion, our case showed that bortezomib and dex-
amethasone regimen alone may be effective in renal recovery
even in patients with severe RF in MM. Future studies
comparing outcomes between combination strategies and
novel agents alone arewarranted to understand the additional
benefits with mechanical modalities and, importantly, when
the combination strategy would be needed—EuLITE [51] and
MYRE [52] trails are in progress in this regard.
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